key: cord-1017683-px0t3jvp
authors: Christensen, Paul A.; Olsen, Randall J.; Long, S. Wesley; Subedi, Sishir; Davis, James J.; Hodjat, Parsa; Walley, Debbie R.; Kinskey, Jacob C.; Ojeda Saavedra, Matthew; Pruitt, Layne; Reppond, Kristina; Shyer, Madison N.; Cambric, Jessica; Gadd, Ryan; Thakur, Rashi M.; Batajoo, Akanksha; Mangham, Regan; Pena, Sindy; Trinh, Trina; Yerramilli, Prasanti; Nguyen, Marcus; Olson, Robert; Snehal, Richard; Gollihar, Jimmy; Musser., James M.
title: Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
date: 2021-11-11
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2021.10.019
sha: 3b42e6e6b6c5d9ab07ff056bf3a2985e70403deb
doc_id: 1017683
cord_uid: px0t3jvp

Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic. Delta variants of concern are now the focus of intense international attention because they are causing widespread COVID-19 disease globally and are associated with vaccine breakthrough cases. We sequenced the genomes of 16,965 SARS-CoV-2 from samples acquired March 15, 2021 through September 20, 2021 in the Houston Methodist hospital system. This sample represents 91% of all Methodist system COVID-19 patients during the study period. Delta variants increased rapidly from late April onward to cause 99.9% of all COVID-19 cases and spread throughout the Houston metroplex. Compared to all other variants combined, Delta caused a significantly higher rate of vaccine breakthrough cases (23.7% for Delta compared to 6.6% for all other variants combined). Importantly, significantly fewer fully vaccinated individuals required hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. Patients infected with Alpha and Delta variants had several significant differences. Our integrated analysis emphasizes that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.

Delta variants of concern (VOCs) of SARS-CoV-2 such as B.1.617.2, AY. 3, and AY.4 are the focus of intense international concern because they are causing widespread COVID-19 disease in the United States, Southeast Asia, Europe, and elsewhere https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed August 18, 2021) . Vaccine breakthrough cases caused by SARS-CoV-2 variants also have become of considerable public health and biomedical concern worldwide 2-6 . To study Delta spread and vaccine breakthrough cases in metropolitan Houston, we sequenced the genomes of 16,965 SARS-CoV-2 from patient samples acquired March 15, 2021 through September 20, 2021 using an Illumina NovaSeq 6000 instrument and methods described previously 7, 8 . This period includes the time from initial identification of Delta-related VOCs in late April in our large Houston Methodist healthcare system until Delta VOCs continuously caused the supermajority (99.9%) of all new cases. The sequenced sample is 91% of the 18,736 total COVID-19 cases diagnosed in our health system during the study period. We also compared characteristics of patients infected J o u r n a l P r e -p r o o f with Alpha and Delta VOCs, an analysis that identified several significant differences between patients infected with these two variants.

Specimens were obtained from registered patients at Houston Methodist hospitals, associated facilities (e.g., urgent care centers), and institutions in the Houston metropolitan region that use our laboratory services. The great majority of individuals had signs or symptoms consistent with COVID-19 disease. For analyses focusing on the Delta family variants, a comprehensive sample of genomes obtained from March 15, 2021 through September 20, 2021 was used. This time frame was chosen because it represents the period during which the downturn of our third wave was occurring, and soon after we identified the first Delta variant case in our health care system. 

The first Houston Methodist patient infected with a Delta family variant was identified in mid-April 2021, a time when the Alpha VOC was responsible for most COVID-19 cases in metropolitan Houston, and the area was experiencing a steady downturn in total number of new COVID-19 cases (Figure 1 ). Delta VOCs slowly increased in frequency, but beginning in early July a sharp uptick of COVID-19 cases caused by these VOCs To understand the geospatial distribution of Delta in metropolitan Houston, we acquired patient metadata from the electronic medical record by standard informatics methods, and home address zip codes were used to visualize virus spread (Figure 2 ).

Delta VOCs were widely distributed throughout metropolitan Houston, with 334 distinct J o u r n a l P r e -p r o o f zip codes represented (Figure 2) , indicative of the ability of Delta variants to spread very effectively and rapidly between individuals. Analysis of Delta VOCs dissemination over time illustrated the rapid spread of these variants throughout the Houston metroplex (Figure 2 ). Table 1) , infection of partially immunized hosts, and prolonged infections occurring in relatively immunocompromised individuals [10] [11] [12] [13] [14] [15] [16] . In this regard, some of our patients had a history of cancer and organ transplants (data not shown). Patients infected with the same subvariant usually lived in different zip codes and generally had no apparent epidemiological link, consistent with the ability of Delta to spread very rapidly. In some cases there were clear epidemiologic links between patients infected with the same subvariant, including being members of the same household.

There is a considerable lack of detailed information about patients in the United States with COVID-19 caused by Delta VOCs J o u r n a l P r e -p r o o f (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021, last accessed August 18, 2021) . Compared to all other patients in the time frame studied, there was no significant difference in sex, but patients infected with Delta were significantly but modestly younger (Table 1) . However, Delta variant patients were admitted significantly less frequently than other patients and had a significantly longer median hospital length of stay, but there was no significant difference in mortality rate ( Table 1) . Delta cases were more likely to be Asian (consistent with multiple recent entry points from abroad) and Caucasian and less likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values on initial diagnosis (a proxy for higher virus load, a finding consistent with increased transmissibility of Delta variants).

In addition, Delta variants caused a significantly much higher rate of vaccine breakthrough cases (23.7% compared to 6.6% for all other variants combined) ( Table   1 ). Consistent with Delta causing an increased number of vaccine breakthrough cases, it has been reported that this variant has reduced sensitivity to antibody neutralization in vitro 14 .

The occurrence of a prominent third wave of COVID-19 cases in Houston caused by the Alpha VOC (Figure 1 ) provided the opportunity of compare and contrast large disease waves caused by two genetically distinct SARS-CoV-2 genotypes. For this analysis we included Alpha VOC cases beginning January 1, 2021, because that time was soon after our first recorded Houston Methodist case caused by this variant. The number of J o u r n a l P r e -p r o o f Delta cases studied (n = 13,043) was much greater than the number of Alpha cases (n = 3,238) ( Table 2 ). The two patient populations differed significantly in many characteristics, including median age, ethnicity, median PCR Ct level, admission rates, maximum respiratory support, rate of vaccine breakthrough, median length of stay, and mortality ( Table 2) .

We next analyzed vaccine breakthrough cases ( Table 3) . We found 3,346 of the 16,965 total patients (19.7%) for whom we have genome sequence data met the CDC definition of vaccine breakthrough cases ( Table 1 and Table 3 ). There was no simple relationship (Table 1 and Table 3 ).

The Lambda variant of interest was first reported in November 2020. It has very recently attracted widespread media and public interest because it has caused large numbers of infections in Peru and Ecuador, and has been reported to cause COVID-19 in the U.S 24, 25 (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/, last accessed September 2, 2021). There has been speculation that Lambda may become numerically prominent in the United States and other countries, in part because its spike protein differs immunologically and has been reported to be partially resistant in vitro to vaccine-induced sera and therapeutic monoclonal antibodies [26] [27] [28] . Because of this concern, we inspected our large genome sequence database to determine if Lambda was present, and if so, had it increased substantially in the Houston metropolitan region.

The analysis identified only eight cases caused by this variant of interest, the first one identified in our Houston Methodist patient population in mid-July 2021 ( Figure 4A) .

These patients lived in several non-contiguous zip codes throughout the metroplex, that is, were not restricted to a single geographic area of greater Houston (Figure 4A, B) .

The Mu VOI was initially identified in Colombia in January, 2021, and has been reported to account for 39% of cases in that country 29 . Mu also has been found in many other countries worldwide, and recently it was reported that the Mu variant has increased resistance in vitro to antibodies elicited by vaccination with BNT162b2 and natural J o u r n a l P r e -p r o o f infection by SARS-CoV-2 30 . We identified 53 cases of COVID-19 caused by the Mu VOI, and similar to the Lambda these cases were distributed in multiple areas in the Houston metropolitan region (Figure 4C, D) .

In this work, we analyzed SARS-CoV-2 Delta VOCs population genomics and patient https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed August 18, 2021) . In less than five months, Delta VOCs increased from an initial documented case in our large patient population to cause 99.9% of all cases in our healthcare system. The rapid increase in Delta cases we documented is responsible for a prominent fourth wave of COVID-19 disease in Houston that is ongoing (Figure 1 ).

Our findings are consistent with Delta VOCs epidemiologic data reported from other regions of the US.

We found that Delta was significantly more likely to cause vaccine breakthrough cases ( Table 1 and Table 3) Our study has several limitations that should be noted. Although we sequenced the genomes of SARS-CoV-2 causing 91% of all Houston Methodist COVID-19 cases in the study period, this sample represents only approximately 5% of cases reported in the metropolitan region. We believe it is possible that our patient populations underrepresent certain demographic groups, for example including homeless individuals and pediatric patients. The great majority of the samples sequenced in this study were obtained from symptomatic patients. Thus, it is possible that our sample failed to identify virus genotypes that are preferentially represented in asymptomatic individuals.

However, given that at the end of the study Delta represented 99.9% of all cases, we think it unlikely that variants associated with asymptomatic individuals would be substantially different, although this is a formal possibility.

In the aggregate, our data add critical new information to the finding that these three vaccines are highly efficacious in decreasing severe COVID-19 disease, hospitalizations, and deaths 6, 20, 23 . Further, the present study highlights the importance of analyzing SARS-CoV-2 genome data integrated with linked patient metadata and stresses the need to continue to do this in near-real time as the pandemic continues, the virus evolves, and new variants with potentially increased fitness are generated.

Analyses of this type are also important in the context of vaccine formulation and long COVID, an increasing health and economic problem globally. interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. subvariants represented by at least 100 samples. S1-NTD, S1 domain-aminoterminal domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain.

Data presented in this image builds on information that has been previously published. 7 

Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Wiener-Well Y: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern

Trajectory of Growth of Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in

Analysis of the ARTIC version 3 and version 4 SARS-CoV-2 primers and their impact on the detection of the G142D amino acid substitution in the spike protein

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

SARS-CoV-2 evolution during treatment of chronic infection

Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of the BNT162b2 Covid-19

Vaccine against the B.1.1.7 and B.1.351 Variants

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2

Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern

The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies

SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines

Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2

Mu variant by convalescent and vaccine sera

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections

BE: Virological and serological kinetics of SARS-CoV

Delta variant vaccine-breakthrough infections: a multi-center cohort study

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Shedding of Infectious SARS-CoV-2 Despite Vaccination

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel

High Flow Oxygen

Mortality Alive 12496 (95.8%) 3755 (95.7%) 16251 (95.8%)

Fisher's exact test Odds Ratio

Vaccine No vaccine 9483

BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay J

Low Flow Oxygen 1741

Mortality Alive 12496 (95.8%) 3073 (94.9%) 15569 (95.6%)

Fisher's exact test Odds Ratio

Vaccine No vaccine 9483

BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

We thank Drs. Marc Boom and Dirk Sostman for their ongoing support and Dr. Sasha